Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
104 Leser
Artikel bewerten:
(0)

Interleukin Genetics, Inc. to Present at the 2010 Rodman & Renshaw Annual Global Investment Conference

WALTHAM, Mass., Sept. 8 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (OTCQB: ILIU) announced today that CEO Lewis H. Bender will present at the Rodman & Renshaw Annual Global Investment Conference, taking place at the New York Palace Hotel in New York City, Sept. 12-15, 2010. The corporate presentation is scheduled for Tuesday, Sept. 14 at 11:15 a.m. in the Spellman Salon on the 5th Floor.

In addition, Mr. Bender is scheduled to participate in a panel discussion titled "Navigating the Changing Regulatory Landscape of Laboratory Developed Tests" on Sept. 14 at 8 a.m. in the Spellman Salon on the 5th Floor.

Company management will be available for one-on-one meetings with investors participating in the Rodman & Renshaw Global Investment Conference. For those who would like to schedule an appointment with Interleukin Genetics' management, please contact your Rodman & Renshaw representative.

The presentation will be webcast live at http://www.ilgenetics.com/, where it will also be archived for 90 days.

About Interleukin Genetics

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics' flagship products include its proprietary PST® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists, and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, MA and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratories Improvements Act (CLIA). For more information please visit http://www.ilgenetics.com/.

Interleukin Genetics, Inc.

CONTACT: Erin Walsh, Interleukin Genetics, Inc., +1-781-419-4707,
ewalsh@ilgenetics.com

Web Site: http://www.ilgenetics.com/

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.